These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18798134)

  • 21. Current aspects of Fabry's disease.
    Torregrosa JV
    Med Clin (Barc); 2018 Sep; 151(5):196-197. PubMed ID: 29523338
    [No Abstract]   [Full Text] [Related]  

  • 22. Cutaneous polyarteritis nodosa in a patient with fabry disease.
    Chen HJ; Yang CC; Hsiao CH; Chu CY
    Arch Dermatol; 2008 Jan; 144(1):122-3. PubMed ID: 18209188
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
    Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
    Das AM; Naim HY
    Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge].
    Weidemann F; Sommer C; Duning T; Lanzl I; Möhrenschlager M; Naleschinski D; Baron R; Breunig F; Schaefer R; Strotmann J; Wanner C
    Med Klin (Munich); 2009 Jan; 104(1):10-9. PubMed ID: 19142592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Anderson-Fabry disease.
    Linhart A
    Heart; 2008 Feb; 94(2):138-9. PubMed ID: 18195119
    [No Abstract]   [Full Text] [Related]  

  • 27. Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target.
    Germain DP
    Kidney Int; 2024 Feb; 105(2):237-239. PubMed ID: 37714429
    [No Abstract]   [Full Text] [Related]  

  • 28. 8th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities in 2024.
    Nephron; 2024; 148 Suppl 1():1-76. PubMed ID: 38934177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection and treatment of Fabry disease.
    Breunig F
    Clin Ther; 2008; 30 Suppl B():S45. PubMed ID: 18395137
    [No Abstract]   [Full Text] [Related]  

  • 30. Uveitis and Fabry disease.
    Elstein D; Altarescu G; Zimran A
    Eye (Lond); 2007 Mar; 21(3):448; author reply 448-9. PubMed ID: 17024216
    [No Abstract]   [Full Text] [Related]  

  • 31. [Fabry's disease, recommendation for diagnostics, follow up and treatment in Finland].
    Penttinen M; Kantola I; Nuutila P; Hietaharju A; Honkanen E; Kaitila I; Niskanen L; Savolainen M; Viikari J
    Duodecim; 2004; 120(20):2407-14. PubMed ID: 15641509
    [No Abstract]   [Full Text] [Related]  

  • 32. Does gender parity exist in Fabry disease?
    Percy AK; Kaye EM
    Neurology; 2005 Aug; 65(4):508-9. PubMed ID: 16116105
    [No Abstract]   [Full Text] [Related]  

  • 33. [Lisosomal disease with endocrine abnormality].
    Eto Y
    Nihon Rinsho; 2006 Sep; Suppl 3():579-81. PubMed ID: 17022612
    [No Abstract]   [Full Text] [Related]  

  • 34. [A late formed diagnosis!].
    Thijssen-Bos F; Slee PH
    Ned Tijdschr Geneeskd; 1988 Nov; 132(48):2185-7. PubMed ID: 2849721
    [No Abstract]   [Full Text] [Related]  

  • 35. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
    Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
    Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent claudication -- atypical presentation, diagnosis and treatment.
    Taylor I; Dennett X; Nicholls K; Tubridy N
    J Clin Neurosci; 2004 Sep; 11(7):783-5. PubMed ID: 15337151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fabry disease--guidelines for diagnosis and management of adult patients].
    Merkler M; Pećin I; Simić I; Muacević-Katanec D; Sućur N; Reiner Z
    Lijec Vjesn; 2014; 136(5-6):133-5. PubMed ID: 25154181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic challenges and new therapies for rare lysosomal storage diseases.
    Hesselgrave B
    Case Manager; 2003; 14(6):48-52. PubMed ID: 14618149
    [No Abstract]   [Full Text] [Related]  

  • 39. [Current practice in Fabry disease: a comprehensive multidisciplinary approach].
    Germain DP
    Presse Med; 2007 Mar; 36 Spec No 1():1S3-6. PubMed ID: 17546760
    [No Abstract]   [Full Text] [Related]  

  • 40. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria.
    Kleinert J; Kotanko P; Spada M; Pagliardini S; Paschke E; Paul K; Voigtländer T; Wallner M; Kramar R; Stummvoll HK; Schwarz C; Horn S; Holzer H; Födinger M; Sunder-Plassmann G
    Transpl Int; 2009 Mar; 22(3):287-92. PubMed ID: 18954370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.